Pharma, Biotech and Generics Industry News | The Pharmaletter
Nov 6, 2024 · India's BIRAC is propelling the country to global biotech leadership. 21 October 2024 As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth.
Amgen to file for Uplinza approval in gMG | The Pharmaletter
Oct 15, 2024 · Amgen to file for Uplizna approval in gMG. Biotechnology. 15 October 2024. US biotech major Amgen (Nasdaq: AMGN) has further strengthened the growing evidence for the use of Uplizna (inebilizumab-cdon) in severe autoimmune diseases. The Californian company has presented positive top-line results from the Phase III MINT trial evaluating the ...
Trump vs Harris—who's on Big Pharma's side?
22 September 2024. Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. While Donald Trump famously accused the industry of "getting away with murder” on prices, the rhetoric from Democrats has been equally stark, with Vice President Kamala Harris boasting she took on ...
Millennium Pharmaceuticals set to buy LeukoSite for $635 million
Oct 17, 1999 · Millennium Pharmaceuticals is hoping to gain access to a stronglate-stage pipeline after agreeing to acquire LeukoSite in a stock deal valued at $635 million. Millennium is offering $35.86 per share for LeukoSite, almost double the latter's closing price on the day of the announcement (October 13) and the deal is expected to close in early 2000.
Wyeth licenses Mochida's portfolio of TRPV1 antagonists
21 January 2008. US drug major Wyeth has licensed Japanese drugmaker Mochida Pharmaceutical's portfolio of transient receptor potential vanilloid sub type 1 (TRPV1) receptor antagonists which have potential as novel painkillers, reports Japan's Corporate News. Under the terms of the deal, Wyeth obtained an exclusive worldwide license for the ...
Novartis rounds off remibrutinib data package ahead of CSU filing
Oct 14, 2024 · At the EADV congress, Novartis presented Phase III data for remibrutinib, a selective Bruton’s tyrosine kinase inhibitor, in chronic spontaneous urticaria (CSU). The 52-week results show significant early improvement in urticaria activity scores compared to placebo. Remibrutinib maintained efficacy and safety, with plans for regulatory submission in 2025, potentially offering a new oral ...
New US Cialis ad to debut at Super Bowl - The Pharma Letter
Feb 2, 2004 · Lilly ICOS will debut a 60-second television ad for its new erectile dysfunction drug Cialis (tadalafil) during the US Super Bowl telecast on February 1. Lilly ICOS began airing 15-second awareness spots for ED during the National Football League's conference championship games on January 18. However, this is the first time TV ads will inform ...
Arda’s $43 million Series A to progress cell depletion therapies
Oct 9, 2024 · Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has raised $43 million in a Series A round. Led by Andreessen Horowitz, the funding will support Arda's novel strategy of eliminating disease-driving cells, rather than targeting proteins, across fibrotic, autoimmune, and metabolic conditions.
Novartis halts Phase II study of LTP001 in idiopathic pulmonary ...
Oct 15, 2024 · Novartis halted its Phase II IPF trial for LTP001, citing non-safety reasons. This move aligns with its strategy to streamline R&D, focusing on cardiovascular, oncology, immunology, and gene/cell therapy. The company aims to bolster key platforms while reducing non-core projects.
Novo Nordisk settles patent lawsuit over Ozempic
Oct 8, 2024 · Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US patent lawsuit over diabetes drug Ozempic (semaglutide). The lawsuit aimed to protect Ozempic’s market exclusivity until 2032. Mylan and Natco Pharma are developing a generic version, with exclusivity for six months after approval.